. 2016 May 20;7(26):39823–39833. doi: 10.18632/oncotarget.9503

Table 1. Characteristics of the randomized trials included in the meta-analysis.

Study	Year	Phase	Line of treatment	Drug delivery	Dominant ethnicity	Treatment comparison	Number of patients	Median age (years)	Female	Never smoker	Activating EGFR-mutant	Jadad score
Aerts	2013	II	Second line	Intercalated	Caucasian	E+DOC or E+PEM	116	62.5	43	9	NA	3
Aerts	2013	II	Second line	Intercalated	Caucasian	E	115	64	40	7	NA
Auliac	2014	II	Second line	Intercalated	Caucasian	E+DOC	75	59.1	14	9	NA	3
Auliac	2014	II	Second line	Intercalated	Caucasian	DOC	76	59.7	18	2	NA
Boutsikou	2013	III	First line	Concurrent	Caucasian	E+DOC+CBP	52	62.5	12	8	NA	3
Boutsikou	2013	III	First line	Concurrent	Caucasian	DOC+CBP	61	65	4	8	NA
Dittrich	2014	II	Second line	Concurrent	Caucasian	E+PEM	76	64	30	10	NA	3
Dittrich	2014	II	Second line	Concurrent	Caucasian	PEM	83	61	34	14	NA
Gatzemeier	2007	III	First line	Concurrent	Caucasian	E+GEM+DDP	580	60	125	NA	NA	3
Gatzemeier	2007	III	First line	Concurrent	Caucasian	E	579	59.1	142	NA	NA
Giaccone	2004	III	First line	Concurrent	Caucasian	G+GEM+DDP	365	59	85	NA	NA	4
Giaccone	2004	III	First line	Concurrent	Caucasian	G	363	61	101	NA	NA
Herbst	2004	III	First line	Concurrent	Caucasian	G+TAX+CBP	345	61	146	NA	NA	3
Herbst	2004	III	First line	Concurrent	Caucasian	G	345	63	133	NA	NA
Herbst	2005	III	First line	Concurrent	Caucasian	E+TAX+DDP	539	62.7	217	72	NA	4
Herbst	2005	III	First line	Concurrent	Caucasian	E	540	62.6	207	44	NA
Hirsch	2011	II	First line	Intercalated	Caucasian	E+TAX+CBP	71		31	21	12	3
Hirsch	2011	II	First line	Intercalated	Caucasian	E	72	NA	44	19	10
Janne	2012	II	First line	Concurrent	Caucasian	E+TAX+CBP	100	60	58	79	33	3
Janne	2012	II	First line	Concurrent	Caucasian	E	81	58	49	64	33
Lee	2013	II	Second line	Intercalated	Asian	E+PEM	78	55.8	58	78	NA	3
Lee	2013	II	Second line	Intercalated	Asian	E or PEM	162	54.9	99	162	NA
Mok	2009	II	First line	Intercalated	Asian	E+GEM+DDP or CBP	76	57.5	22	24	2	3
Mok	2009	II	First line	Intercalated	Asian	GEM+DDP or CBP	78	57	24	28	5
Soria	2015	III	Second line	Concurrent	Asian	G+PEM	133	60	87	88	127	5
Soria	2015	III	Second line	Concurrent	Asian	PEM	132	58	84	91	134
Wu	2013	III	First line	Intercalated	Asian	E+GEM+DDP or CBP	226	59	94	112	49	5
Wu	2013	III	First line	Intercalated	Asian	GEM+DDP or CBP	225	57.3	85	107	48
Yu	2014	II	First line	Intercalated	Asian	G+PEM+DDP	58	55.3	25	29	14	3
Yu	2014	II	First line	Intercalated	Asian	PEM+DDP	59	54.9	34	39	18

Abbreviations: E: erlotinib; G: gefitinib;,DOC: doctaxel; Pem: pemetrexed; TAX: paclitaxel; Gem: gemcitabine; CBP: carboplatin; DDP: cisplatin; NA: not available.